Market Overview

Benzinga's Top Downgrades

Related HTWR
AngioDynamics Q4 Earnings Beat, Revenues Up on Higher Sales
Cepheid Posts Narrower-than-Expected Q2 Loss, Revenues Rise
Related MSFT
Is Apple's $700 Billion Valuation The Largest Of All Time?
Dow, S&P 500 Little Changed Despite Upward 3Q GDP Revision
Tech Rewind: Uber Stirs Up the Pot ... Again (Fox Business)

Analysts at Goldman Sachs downgraded Heartware International (NASDAQ: HTWR) from “neutral” to “sell.” The target price for Heartware International has been lowered from $94 to $73. Heartware's shares closed at $81.26 on Friday.

Analysts at Deutsche Bank downgraded Microsoft (NASDAQ: MSFT) from “buy” to “hold.” The target price for Microsoft is set to $42. Microsoft's shares closed at $39.21 on Friday.

Morgan Stanley downgraded Mindray Medical International (NYSE: MR) from “overweight” to “equal-weight.” The target price for Mindray Medical has been lowered from $44 to $37. Mindray Medical's shares closed at $33.08 on Friday.

Analysts at Credit Suisse downgraded Enbridge (NYSE: ENB) from “outperform” to “neutral.” Enbridge's shares closed at $46.60 on Friday.

Latest Ratings for HTWR

DateFirmActionFromTo
Nov 2014JP MorganMaintainsOverweight
Oct 2014Canaccord GenuityMaintainsBuy
Oct 2014OppenheimerMaintainsOutperform

View More Analyst Ratings for HTWR
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (HTWR + ENB)

Around the Web, We're Loving...

Get Benzinga's Newsletters